The NHS has published final draft guidance recommending abiraterone and its generic variants in combination with androgen deprivation therapy and prednisolone or prednisone as an option for adults with newly diagnosed high-risk hormone‑sensitive metastatic prostate cancer. The decision marks a significant shift from our 2021 guidance, which could not recommend abiraterone because, at the time, it did not represent value…
Ben KempNovember 6, 2025